(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.2%.
Calcimedica's earnings in 2026 is -$15,110,000.On average, 5 Wall Street analysts forecast CALC's earnings for 2026 to be -$16,621,446, with the lowest CALC earnings forecast at -$26,691,122, and the highest CALC earnings forecast at -$3,547,554. On average, 5 Wall Street analysts forecast CALC's earnings for 2027 to be -$33,242,892, with the lowest CALC earnings forecast at -$71,626,808, and the highest CALC earnings forecast at -$3,113,160.
In 2028, CALC is forecast to generate -$13,468,295 in earnings, with the lowest earnings forecast at -$23,988,223 and the highest earnings forecast at -$2,027,174.